296 related articles for article (PubMed ID: 12416792)
1. Differences between COX-2-specific inhibitors: clinical and economic implications.
Sonnenblick EH
Am J Manag Care; 2002 Oct; 8(15 Suppl):S428-30. PubMed ID: 12416792
[No Abstract] [Full Text] [Related]
2. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
[TBL] [Abstract][Full Text] [Related]
3. The coxibs, selective inhibitors of cyclooxygenase-2.
FitzGerald GA; Patrono C
N Engl J Med; 2001 Aug; 345(6):433-42. PubMed ID: 11496855
[No Abstract] [Full Text] [Related]
4. COX-2 inhibitors--a lesson in unexpected problems.
Drazen JM
N Engl J Med; 2005 Mar; 352(11):1131-2. PubMed ID: 15713947
[No Abstract] [Full Text] [Related]
5. [Gastric protective pain therapy. What is the advantage of new COX-2 inhibitors?].
Hinz B; Brune K
MMW Fortschr Med; 2000 Mar; 142(11):39-40. PubMed ID: 10786088
[No Abstract] [Full Text] [Related]
6. [The coxibs, third generation anti-inflammatories].
Sternon J
Rev Med Brux; 2001 Apr; 22(2):100-5. PubMed ID: 11388024
[TBL] [Abstract][Full Text] [Related]
7. The cox-2 inhibitors.
Strassels S
J Mass Dent Soc; 1999; 48(3):43-4. PubMed ID: 10808349
[No Abstract] [Full Text] [Related]
8. [Specific inhibitors of cyclooxygenase type 2] ].
Tomasová-Studýnková J
Vnitr Lek; 2002 May; 48(5):403-8. PubMed ID: 12061207
[TBL] [Abstract][Full Text] [Related]
9. COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease.
Ray WA; MacDonald TM; Solomon DH; Graham DJ; Avorn J
Pharmacoepidemiol Drug Saf; 2003; 12(1):67-70. PubMed ID: 12616850
[No Abstract] [Full Text] [Related]
10. Coxibs and cardiovascular disease.
Fitzgerald GA
N Engl J Med; 2004 Oct; 351(17):1709-11. PubMed ID: 15470192
[No Abstract] [Full Text] [Related]
11. COX-2 inhibitors: no pain, no heart gain?
Harv Heart Lett; 2001 Dec; 12(4):2-4. PubMed ID: 11751079
[No Abstract] [Full Text] [Related]
12. [New study of selective COX-2 inhibitors. Protecting the stomach while risking the heart? (interview by Dr. Beate Schumacher)].
Zeidler H
MMW Fortschr Med; 2001 Sep; 143(35-36):14. PubMed ID: 11584521
[No Abstract] [Full Text] [Related]
13. COX-2 inhibitors: new drugs for the management of pain and inflammation.
Hutchins V; Hutchins B
Dent Today; 2001 Feb; 20(2):56-61. PubMed ID: 12524847
[No Abstract] [Full Text] [Related]
14. COX-2 inhibitors--lessons in drug safety.
Psaty BM; Furberg CD
N Engl J Med; 2005 Mar; 352(11):1133-5. PubMed ID: 15713946
[No Abstract] [Full Text] [Related]
15. COX-2 inhibitors: better than traditional NSAIDs? Vioxx and Celebrex may be no less risky than NSAIDs.
Atkinson HG
Health News; 2002 Aug; 8(8):5. PubMed ID: 12206146
[No Abstract] [Full Text] [Related]
16. [Thinking about the specific cyclooxygenase-2 inhibitors since its recommendation].
Shi G
Zhonghua Nei Ke Za Zhi; 2001 Sep; 40(9):579-80. PubMed ID: 11758234
[No Abstract] [Full Text] [Related]
17. Summaries for patients. The cost-effectiveness of cyclooxygenase-2 inhibitors for treating chronic arthritis.
Ann Intern Med; 2003 May; 138(10):I39. PubMed ID: 12755582
[No Abstract] [Full Text] [Related]
18. The new COX-2 inhibitors: rofecoxib (Vioxx) and celecoxib (Celebrex).
Wynn RL
Gen Dent; 2000; 48(1):16-20. PubMed ID: 11199547
[No Abstract] [Full Text] [Related]
19. [COX-2 specific inhibitors: are NSAIDs and the stomach become reconcilied?].
Bannwarth B
Gastroenterol Clin Biol; 2001 Apr; 25(4 Suppl):B79-84. PubMed ID: 11449148
[No Abstract] [Full Text] [Related]
20. [New anti-inflammatory analgetics--are they needed?].
Paakkari I
Duodecim; 1999; 115(20):2217-24. PubMed ID: 11973925
[No Abstract] [Full Text] [Related]
[Next] [New Search]
